Atıf İçin Kopyala
Cobanoglu N., Ozcelik U., ÇAKIR E., Eyuboglu T. S., PEKCAN S., Cinel G., ...Daha Fazla
PEDIATRIC PULMONOLOGY, cilt.55, sa.9, ss.2302-2306, 2020 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
55
Sayı:
9
-
Basım Tarihi:
2020
-
Doi Numarası:
10.1002/ppul.24854
-
Dergi Adı:
PEDIATRIC PULMONOLOGY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
-
Sayfa Sayıları:
ss.2302-2306
-
Anahtar Kelimeler:
cystic fibrosis, modulator drugs, national registry, TEZACAFTOR-IVACAFTOR
-
Eskişehir Osmangazi Üniversitesi Adresli:
Evet
Özet
Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs.